Key Points
NEW DELHI: The government is likely to reconsider its recent decision to act against pharmaceutical companies manufacturing nutraceuticals, health supplements and drugs in the same facility following objections raised by industry lobby groups...
In a recent diktat, the government said action will be taken against pharma units that are flouting the norms by manufacturing nutraceuticals, health supplements and drugs in the same facility...
Executives of Fope recently met the health secretary and the Drug Controller General of India (DCGI), seeking an exception to select units as was given earlier...
"Subsequently, this concession was extended to all manufacturing establishments by the Drugs Controller General India under his letter dated March 1, 2007, based on the decision of the Drugs Consultative Committee in its 37th meeting."..
As per a recent notice by the DCGI, an enforcement and surveillance drive carried out by the Food Safety and Standards Authority of India (FSSAI) found that many units in Himachal Pradesh have dual licences under FSS Act 2006 and Drugs and Cosmetics Act 1940 for manufacturing nutraceuticals, health supplements and drugs in same factory...
You might be interested in
'Adulterated drugs’ to breakthrough cancer therapy — how India's health & pharma sector fared in 2023
08, Dec, 23The year was eventful with National Medical Commission's flip-flops over controversial decisions, tightening of various norms and launch of made-in-India drugs to treat rare diseases.